Bayesian Decision-optimal Interval Designs for Phase I Clinical Trials by Liu, Suyu & Yuan, Ying
ar
X
iv
:1
30
9.
50
19
v1
  [
sta
t.M
E]
  1
9 S
ep
 20
13
Bayesian Decision-optimal Interval Designs for Phase I Clinical
Trials
Suyu Liu and Ying Yuan*
Department of Biostatistics
The University of Texas MD Anderson Cancer Center
Houston, Texas 77030, U.S.A.
*email: yyuan@mdanderson.org
Abstract
Interval designs are a class of phase I trial designs for which the decision of dose as-
signment is determined by comparing the observed toxicity rate at the current dose with a
prespecified (toxicity tolerance) interval. If the observed toxicity rate is located within the
interval, we retain the current dose; if the observed toxicity rate is greater than the upper
boundary of the interval, we deescalate the dose; and if the observed toxicity rate is smaller
than the lower boundary of the interval, we escalate the dose. The most critical issue for
the interval design is choosing an appropriate interval so that the design has good operating
characteristics. By casting dose finding as a Bayesian decision-making problem, we propose
new flexible methods to select the interval boundaries so as to minimize the probability of
inappropriate dose assignment for patients. We show, both theoretically and numerically,
that the resulting optimal interval designs not only have desirable finite- and large-sample
properties, but also are particularly easy to implement in practice. Compared to existing
designs, the proposed (local) optimal design has comparable average performance, but a
lower risk of yielding a poorly performing clinical trial.
KEY WORDS: Decision error; adaptive design; dose finding; maximum tolerated dose.
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1 Introduction
Numerous phase I trial designs have been proposed to identify the maximum tolerated dose
(MTD) of a new drug, which is typically defined as the dose with a dose-limiting toxicity
probability that is closest to the target toxicity rate. The standard 3+3 design is easy to im-
plement and widely used in practice, but suffers from poor operating characteristics (Storer,
1989; Korn et al., 1994; Ahn, 1998; and Iasonos et al., 2008). To obtain better operating char-
acteristics, O’Quigley, Pepe and Fisher (1990) proposed the continual reassessment method
(CRM), which utilizes the accrued information to continuously update the estimate of the
parametric dose-toxicity model for dose assignment and selection. Durham and Flournoy
(1994) proposed the biased coin design, which determines the dose assignment based on the
toxicity outcome from the most recently treated patient. Whitehead and Brunier (1995)
introduced a decision-theoretic approach geared to optimize information gathering for esti-
mation of the MTD. Wetherill (1963) proposed a k-in-a-row design that utilizes observations
from the k most recently treated patients to make the decision of dose assignment. Babb,
Rogatko and Zacks (1998) proposed a dose escalation method with overdose control that
directly controls the probability of overdosing. Lin and Shih (2001) investigated the statis-
tical properties of the “A+B” designs and derived the exact formulae for the corresponding
statistical quantities. Leung and Wang (2001) proposed an up-and-down design based on
isotonic regression without making any parametric dose-response assumptions. Tsutakawa
(1967) and Gezmu and Flournoy (2006) investigated the group up-and-down design for which
the patients are treated in groups or cohorts. Chevret (2006), Ting (2006) and Gerke and
Siedentop (2008) provided comprehensive reviews of dose-finding methods for phase I clinical
trials.
The interval design, a term coined by Oron, Azriel and Hoff (2011), is a relatively new
class of phase I trial designs, for which the dose transition is defined by the relative location
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of the observed toxicity rate (i.e., the number of patients who experienced toxicity divided
by the total number of patients treated) at the current dose with respect to a prespecified
toxicity tolerance interval. If the observed toxicity rate is located within the interval, we
retain the current dose; if the observed toxicity rate is greater than the upper boundary
of the interval, we deescalate the dose; and if the observed toxicity rate is smaller than
the lower boundary of the interval, we escalate the dose. Yuan and Chappell (2004) first
suggested using a (tolerance) interval to determine dose escalation and deescalation. Ivanova,
Flournoy and Chung (2007) developed a more formal interval design, called the cumulative
cohort design. That design was further extended to ordinal and continuous outcomes based
on a t-statistic (Ivanova and Kim, 2009). The modified toxicity probability interval design
proposed by Ji et al.(2010) also utilized the idea of a tolerance interval to divide the posterior
distribution of the toxicity probability of the current dose into three regions for dose finding.
One advantage of interval designs is that they are very simple to implement in practice.
Because the interval is prespecified, during trial conduct, the decision of which dose to
administer to the next cohort of patients does not require complicated computations, but only
a simple comparison of the observed toxicity rate at the current dose with the prespecified
interval boundaries. Compared to other similarly easy-to-implement designs, e.g., up-and-
down designs, the interval design is more efficient because it uses all the information from
the cumulative data at the current dose to determine the next dose assignment. Recently,
Oron, Azriel and Hoff (2011) showed that the interval design provides a convergence property
similar to that of the CRM. The interval design converges almost surely, at a
√
n rate, to
exclusive allocations at a dose level for which the true toxicity rate is within the interval.
Under the interval design, the selection of an appropriate tolerance interval is critical
for the performance of the design because the dose transition and assignment are entirely
determined by this prespecified interval. Ivanova, Flournoy and Chung (2007) suggested
selecting the interval by an exhaustive numerical search over the group up-and-down designs
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based on its large-sample property. In this article, motivated by clinical practice, we propose
a more flexible, finite-sample based approach to selecting the interval boundaries, and use it
to develop two optimal interval designs.
The idea behind our method is straightforward. The conduct of phase I trials can be
essentially viewed as a sequence of decision-making steps of dose assignment for patients who
are sequentially enrolled into the trial. At each moment of decision making, based on the
observed data, we take one of three actions: escalate, deescalate or retain the current dose.
Under the standard assumption that efficacy monotonically increases with toxicity, an ideal
trial design would escalate the dose when the current dose is below the MTD in order to
avoid treating a patient at subtherapeutic dose levels; deescalate the dose when the current
dose is above the MTD in order to avoid exposing a patient to overly toxic doses; and retain
the same dose level when the current dose is equal (or close) to the MTD. However, such an
ideal design is not available in practice because we do not know whether the current dose
is actually below, above or equal (or close) to the MTD, and need to infer that information
and make decisions based on the data collected from patients who have been enrolled in
the trial. Given the randomness of the observed data and small sample sizes of phase I
trials, the decisions of dose assignment we make are often incorrect, e.g., we may escalate
(or deescalate) the dose when it is actually higher (or lower) than the MTD, which results in
overly aggressive (or conservative) dose escalation and treating excessive numbers of patients
at dose levels above (or below) the MTD. From a practical and ethical viewpoint, it is highly
desirable to minimize such decision errors so that the actual design behaves as closely as
possible to the ideal (error-free) design. Motivated by this goal, we cast dose finding as a
sequential decision-making problem, and develop interval designs that minimize the expected
decision error rate for trial conduct. The proposed designs are simpler to implement than
the CRM, and the simulation study shows that they yield good operating characteristics
that are comparable to or better than those of the CRM.
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The remainder of this article is organized as follows. In Section 2, we formulate dose
finding as a sequential decision-making problem and propose designs to minimize the decision
errors of dose assignment during trial conduct. In Section 3, we present simulation studies
to compare the operating characteristics of the new designs with those of some available
designs. We conclude with a brief discussion in Section 4.
2 Method
2.1 Interval design
Assume that a total of J prespecified doses are under investigation, and let φ denote the
target toxicity rate specified by physicians. We assume that patients are treated in cohorts
but allow the cohort size to vary from one cohort to another. Interval designs can be generally
described as follows:
1. Patients in the first cohort are treated at the lowest dose level.
2. At the current dose level j, assume that a total (or the cumulative number) of nj
patients have been treated, and mj of them have experienced toxicity. Let pˆj = mj/nj
denote the observed toxicity rate at dose level j, and λ1j(nj , φ) and λ2j(nj, φ) denote
the prespecified lower and upper (or dose escalation and deescalation) boundaries of
the interval, respectively, with 0 ≤ λ1j(nj , φ) < λ2j(nj , φ) ≤ 1. To assign a dose to the
next cohort of patients,
• if pˆj ≤ λ1j(nj , φ), we escalate the dose level to j + 1;
• if pˆj ≥ λ2j(nj , φ), we deescalate the dose level to j − 1;
• otherwise, i.e., λ1j(nj, φ) < pˆj < λ2j(nj , φ), we retain the same dose level, j.
To ensure that the dose levels of the treatment always remain within the prespecified
dose range, the dose escalation/deescalation rule requires some adjustments when j
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is at the lowest or highest level. That is, if j = 1 and pˆj ≥ λ2j(nj , φ) or j = J and
pˆj ≤ λ1j(nj , φ), the dose remains at the same level, j.
3. This process is continued until the maximum sample size is reached.
This design is more general than the existing interval designs (e.g., Ivanova, Flournoy and
Chung, 2007; Oron, Azriel and Hoff, 2011), in the sense that it allows the interval boundaries
λ1j(nj, φ) and λ2j(nj , φ) to depend on both dose level j and nj (i.e., the number of patient
that have been treated at dose level j), whereas the existing interval designs assume that
the interval boundaries are independent of j and nj .
2.2 Local optimal interval design
In the interval design, the selection of the interval boundaries λ1j(nj , φ) and λ2j(nj , φ) is
critical because these two parameters essentially determine the operating characteristics of
the design. To simplify the notations, we suppress the arguments nj and φ in λ1j(nj , φ)
and λ2j(nj , φ). In the following subsection, we describe a method to select λ1j and λ2j to
minimize incorrect decisions of dose escalation and deescalation during the trial conduct.
For convenience, we call the resulting design the local optimal interval design because the
optimization is anchored to three point (or local) hypotheses.
2.2.1 Minimizing the local decision error
In order to minimize incorrect decisions of dose assignment, we first formally define the
correct and incorrect decisions. Letting pj denote the true toxicity probability of dose level
j for j = 1, . . . , J , we formulate three point hypotheses:
H0j : pj = φ
H1j : pj = φ1 (1)
H2j : pj = φ2,
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where φ1 denotes the highest toxicity probability that is deemed subtherapeutic (i.e., below
the MTD) such that dose escalation should be made, and φ2 denotes the lowest toxicity
probability that is deemed overly toxic such that dose deescalation is required. For simplicity,
we will alter the notation slightly by dropping subscript j from H0j , H1j and H2j wherever
such alterations do not cause confusion.
Specifically, H0 indicates that the current dose dj is the MTD and we should retain
the current dose to treat the next cohort of patients; H1 indicates that the current dose
is subtherapeutic (or below the MTD) and we should escalate the dose; and H2 indicates
that the current dose is overly toxic (or above the MTD) and we need to deescalate the
dose. Therefore, the correct decisions under H0, H1 and H2 are retainment, escalation and
deescalation (each based on the current dose level), denoted as R, E and D, respectively.
Correspondingly, the incorrect decisions under H0, H1 and H2 are R¯, E¯ and D¯, respectively,
where R¯ denotes the decisions complementary to R (i.e., R¯ includes E and D), and D¯ and
R¯ denote the decisions complementary to D and R.
We note that herein the purpose of specifying three hypotheses, H0, H1 and H2, is not to
represent the truth and conduct hypothesis testing, but just to indicate the cases of special
interest under which we optimize the performance of our design. In particular, H1 and
H2, or more precisely δ1 = φ − φ1 and δ2 = φ2 − φ, represent the minimal differences (or
effect sizes) of practical interest to be distinguished from the target toxicity rate φ (or H0),
under which we want to minimize the average decision error rate for the trial conduct. A
difference smaller than δ1 and δ2 may not be of practical importance, and a larger difference
will lead to a smaller error rate because it is more easily distinguished from φ than φ1 and φ2.
This approach is analogous to sample size determination, for which we first specify a point
alternative hypothesis to represent the minimal effect size of interest and then determine the
sample size to ensure a desirable power under that hypothesis.
Under the Bayesian paradigm, we assign each of the hypotheses a prior probability of
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being true, denoted as πkj = pr(Hkj), k = 0, 1, 2. Then under the proposed design, the
probability of making an incorrect decision (the decision error rate), denoted as α(λ1j , λ2j),
at each of the dose assignments is given by
α(λ1j, λ2j)
= pr(H0j)pr(R¯|H0j) + pr(H1j)pr(E¯ |H1j) + pr(H2j)pr(D¯|H2j) (2)
= pr(H0j)pr(mj ≤ njλ1j ormj ≥ njλ2j |H0j) + pr(H1j)pr(mj > njλ1j|H1j)
+pr(H2j)pr(mj < njλ2j |H2j)
= π0j{Bin(njλ1j ;nj, φ) + 1−Bin(njλ2j − 1;nj, φ)}+ π1j{1− Bin(njλ1j ;nj , φ1)}
+π2jBin(njλ2j − 1;nj, φ2)
where Bin(b;n, φ) is the cumulative density function of the binomial distribution with size
and probability parameters n and φ, evaluated at the value b. It can be shown that the
decision error rate α(λ1j, λ2j) is minimized when
λ1j =
log
(
1− φ1
1− φ
)
+ n−1j log
(
π1j
π0j
)
log
(
φ(1− φ1)
φ1(1− φ)
) (3)
λ2j =
log
(
1− φ
1− φ2
)
+ n−1j log
(
π0j
π2j
)
log
(
φ2(1− φ)
φ(1− φ2)
) . (4)
The derivation of this result (see the Appendix) reveals that the values of λ1j and λ2j
are actually the boundaries at which the posterior probabilities of H1 and H2, respectively,
become more likely than that of H0, i.e., λ1j = argmaxpˆj(pr(H1|nj, mj) > pr(H0|nj , mj))
and λ2j = argminpˆj(pr(H2|nj, mj) > pr(H0|nj, mj)). This intuitive interpretation of λ1j and
λ2j provides a natural justification for our dose assignment rule. That is, we should escalate
the dose if pˆj ≤ λ1j because the observed data support that H1 is more likely than H0 (i.e.,
the current dose j is below the MTD); and we should deescalate the dose if pˆj ≥ λ2j because
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the observed data support that H2 is more likely than H0 (i.e., the current dose j is above
the MTD).
In addition, if we assign equal prior probabilities to three hypotheses (i.e., π0j = π1j =
π2j = 1/3), the values of λ1j and λ2j simply become the likelihood-ratio hypothesis-testing
boundaries. In this case, the value of λ1j is always located between φ1 and φ and the value
of λ2j is always located between φ and φ2 (i.e., φ1 < λ1j < φ and φ < λ2j < φ2). Figure 1
shows how λ1j and λ2j change with respect to φ1 and φ2 when φ = 0.25. We can see that
when φ1 and φ2 are symmetric around φ (i.e., δ1 = δ2), the resulting λ1j and λ2j are also
close to, although not exactly symmetric around φ. Interestingly, based on equations (3)
and (4), it is easy to see that when π0j = π1j = π2j , λ1j and λ2j are invariant to both dose
level j and the accumulative sample size nj. This property is appealing in practice because
in this case the same pair of interval boundaries can be conveniently used throughout the
trial, regardless of the dose level and the number of patients treated in the trial, which thus
greatly simplifies the trial conduct.
2.2.2 Design properties
Cheung (2005) introduced the concept of coherence for trial design and defined it as the
design property by which dose escalation (or deescalation) is prohibited when the observed
toxicity rate in the most recently treated cohort is more (or less) than the target toxicity
rate. Because that definition is based on the response from only the most recently treated
cohort, ignoring the responses from cohorts previously enrolled and treated, herein we refer
to it as short-memory coherence. As an extension, we define long-memory coherence as the
design property by which dose escalation (or deescalation) is prohibited when the observed
toxicity rate in the accumulative cohorts at the current dose is more (or less) than the
target toxicity rate. From a practical view point, long-memory coherence is a more relevant
design property for conducting clinical trials than short-memory coherence. The greater
9
relevance can be seen in the practical judgment of clinicians when they determine whether
dose escalation (or deescalation) is plausible. It is preferable for clinicians to base their
decision on the toxicity data from all patients treated at the current dose rather than from
just 2 or 3 patients in the most recently treated cohort, which could provide highly variable
observations due to the small sample size of the cohort (i.e., rarely more than 3) and patient
heterogeneity. As shown in the Appendix, the proposed local optimal interval design has the
following finite-sample property.
Theorem 1. When setting π0j = π1j = π2j , the proposed local optimal interval design is
long-memory coherent in the sense that the probability of dose escalation (or deescalation)
is zero when the observed toxicity rate pˆj at the current dose is higher (or lower) than the
target toxicity rate φ.
This finite-sample property makes the local optimal design very appealing in practice
because it automatically satisfies the following (ad hoc) safety requirement often imposed
by clinicians: dose escalation is not allowed if the observed toxicity rate at the current
dose is higher than the MTD. Because the local optimal interval design uses the toxicity
information from previously treated patients to make the decision of dose transition, it is
not short-memory coherent. We note that the commonly used version of the CRM, which
does not allow a dose to be skipped, is not short-memory coherent either, especially at the
beginning of the trial and when using an informative prior.
We now turn to another important property of the design — the MTD selection. Under
the proposed optimal dose assignment, we tend to treat patients at (or close to) the MTD,
which facilitates the MTD selection at the end of the trial because most data and statistical
power are concentrated around the MTD. Since limnj→∞ λ1j = log(
1−φ1
1−φ
)/log(φ(1−φ1)
φ1(1−φ)
) ≡ λ˜1
and limnj→∞ λ2j = log(
1−φ
1−φ2
)/log(φ2(1−φ)
φ(1−φ2)
) ≡ λ˜2, it can be shown that the proposed design
10
has the following asymptotic dose-selection property.
Theorem 2. Dose allocation in the local optimal interval design converges almost surely
to dose level j∗ if pj∗ ∈ (λ˜1, λ˜2) and dose level j∗ is the only dose satisfying pj∗ ∈ [λ˜1, λ˜2].
If no dose level satisfies pj ∈ (λ˜1, λ˜2) but φ ∈ [p1, pJ ], the local optimal interval design
would eventually oscillate almost surely between the two dose levels at which the associated
toxicity probabilities straddle the target interval. If there are multiple dose levels satisfying
pj ∈ (λ˜1, λ˜2), the local optimal interval design will converge almost surely to one of these
levels.
The proof of this result is similar to that of Oron, Azriel and Hoff (2011), noting that
λ1j and λ2j converge to constants λ˜1 and λ˜2.
2.2.3 Practical implementation
To use the local optimal interval designs in practice, we need to specify the values of φ1
and φ2. In general, we should avoid setting the values of φ1 and φ2 very close to φ. This
is because the small sample sizes of typical phase I trials prevent us from differentiating
the target toxicity rate from the rates close to it. In addition, in most clinical applications,
the target toxicity rate is often a rough guess, and finding a dose level with a toxicity
rate reasonably close to the target rate will still prove to be of interest to the investigator.
Based on our experience with phase I oncology trials and the operating characteristics of the
proposed design, we find that φ1 ∈ [0.5φ, 0.7φ] and φ2 ∈ [1.3φ, 1.5φ] are reasonable values
for most clinical applications. As default values, we recommend φ1 = 0.6φ and φ2 = 1.4φ
(i.e., 40% deviation from the target) for general use. For example, if the target toxicity is
0.25, we may set φ1 = 0.15 and φ2 = 0.35.
The other parameters we need to specify for the trial design are πkj, the prior probability
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of the hypothesis Hkj, k = 0, 1, 2. As πkj ’s represent the prior probabilities that dose level
j is below, equal to or above the MTD, their values can be directly elicited from physicians
by asking them how likely it is that each of J doses is below, equal to or above the MTD.
When such prior information is not available, as is often the case in practice, we can take a
“noninformative” approach by assuming that the current dose has equal prior probabilities
of being below, equal to or above the MTD. Since the interval design examines the dose levels
one at a time (i.e., the current dose level) without borrowing information from other dose
levels, and the current dose level can be at any level from 1 to J , this noninformative approach
effectively results in the noninformative prior π0j = π1j = π2j = 1/3. One advantage
of using such a noninformative prior is that the resulting interval boundaries λ1j and λ2j
are invariant to dose level j and the number of patients nj . Therefore, the same pair of
boundaries can be conveniently used throughout the trial for dose assignment, regardless of
the dose level and the number of enrolled patients. Table 1 provides the interval boundaries
for some commonly encountered target toxicity rates in oncology under the noninformative
prior π0j = π1j = π2j = 1/3. It seems appealing to specify increasing prior probabilities
for π2j (i.e., π21 < π22 < . . . , < π2J ) to reflect that toxicity monotonically increases with
dose levels. However, based on numerical studies, we found that such an approach did not
improve the performance of the design (results are not shown). This may be because the
monotonicity of the dose-toxicity relationship has been (implicitly) incorporated into the
design through the dose escalation rule (i.e., we escalate the dose because we assume that
the next higher dose level is more toxic), and thus using ordered priors will not bring enough
extra information to improve the design performance.
The local optimal interval design is very easy to implement in practice. Once we specify
the design parameters as described above, the interval boundaries λ1j and λ2j can be easily
calculated at the trial design phase based on equations (3) and (4). Then during the trial
conduct, clinicians can simply count the number of patients who experience toxicity and
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compare the observed toxicity rate pˆj with the prespecified interval boundaries λ1j and λ2j
to determine dose assignment until the trial is completed.
After the trial is completed, we need to select a dose level as the MTD. We propose to
select the MTD based on {p˜j}, the isotonically transformed values of the observed toxicity
rates {pˆj}. Specifically, we select as the MTD dose j∗, for which the isotonic estimate of
toxicity rate p˜j∗ is closest to φ; if there are ties for p˜j∗, we select from the ties the highest dose
level when p˜j∗ < φ or the lowest dose level when p˜j∗ > φ. The isotonic estimates {p˜j} can
be obtained by applying the pooled–adjacent-violators algorithm (PAVA) (Barlow; 1972) to
{pˆj}. Operatively, the PAVA replaces any adjacent pˆj ’s that violate the nondecreasing order
by their (weighted) average so that the resulting estimates p˜j’s become monotonic. In the
case in which the observed toxicity rates are monotonic, p˜j and pˆj are equivalent. We note
that besides the above method, any other reasonable dose selection procedure can be used
to select the MTD for the local optimal design, as the MTD selection and dose transition
rules are two relatively independent components of the trial design, both conceptually and
operatively.
One practical issue largely ignored in the previously proposed interval designs involves
the risk of assigning too many patients to an overly toxic dose. Because interval designs
do not “look” ahead, but instead use only the toxicity information at the current dose level
to determine the dose escalation decision, the dose assignment will bounce back and forth
between two adjacent doses when one of them is much lower than the MTD and the other is
much higher than the MTD. To avoid this result of assigning too many patients to the overly
toxic dose, we propose to impose the following dose elimination rule when implementing the
local optimal interval design.
If pr(pj > φ|mj , nj) > 0.95 and nj ≥ 3, dose levels j and higher are eliminated
from the trial, and the trial is terminated if the first dose level is eliminated,
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where pr(pj > φ|mj, nj) > 0.95 can be evaluated based on a beta-binomial model, assuming
that m follows a binomial distribution (with size and probability parameters n and pj) and
pj follows a vague beta prior, e.g., pj ∼ beta(0.1, 0.1). Based on our experience, rather
than repeatedly evaluating the above dose elimination rule in real time during the trial
conduct, medical researchers often prefer to enumerate the dose elimination boundaries for
each possible value of nj before the initiation of the trial and include these boundaries in the
trial protocol. Therefore, when conducting the trial, they can determine dose elimination
by simply examining whether the number of patients experiencing toxicity at the current
dose, i.e., mj , exceeds the elimination boundaries. Table 2 (in the bottom row) provides
the elimination boundaries for φ = 0.25. For example, when the number of patients treated
at the current dose nj = 4, we need to eliminate that dose and higher doses if 3 or more
patients experience toxicity.
To facilitate practitioners applying the proposed designs, we have prepared easy-to-use
software (written in R) to calculate the interval and dose elimination boundaries and select
the MTD. The software is available upon request.
2.3 Global optimal interval design
We have discussed the local optimal interval design, which minimizes the decision error under
the three point hypotheses given by equation (1). In this section, we discuss a global optimal
interval design, which accounts for all possible values of pj by specifying three composite
hypotheses. In the global optimal design, values of λ1j and λ2j are chosen to minimize the
average decision error over the whole support of pj, i.e., pj ∈ [0, 1]. The contrast between
the local and global optimal interval designs is somewhat analogous to the uniformly most
powerful tests for simple hypotheses versus composite hypotheses in the frequentist testing
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framework. Specifically, we define three composite hypotheses,
H0j : φ1 < pj < φ2
H1j : 0 ≤ pj ≤ φ1
H2j : φ2 ≤ pj ≤ 1,
where H1j indicates that dose level j is subtherapeutic and we should escalate the dose;
H2j indicates that dose level j is overly toxic and we should deescalate the dose; and H0j
indicates that dose level j is close to the MTD and we should retain the same dose level.
Under each hypothesis, we assign the toxicity probabilities pj a noninformative uniform
prior:
f(pj|H0j) = Unif(φ1, φ2)
f(pj|H1j) = Unif(0, φ1) (5)
f(pj|H2j) = Unif(φ2, 1).
Then the global decision error rate is given by
αg(λ1j , λ2j)
= pr(H0j)
∫
f(pj|H0j)pr(R¯|pj, H0j) dpj + pr(H1j)
∫
f(pj |H1j)pr(E¯ |pj, H1j) dpj
+pr(H2j)
∫
f(pj|H2j)pr(D¯|pj, H2j) dpj (6)
= π0j + π1j +
b1j∑
y=0
[
π0j{Beta(φ2; y + 1, nj − y + 1)− Beta(φ1; y + 1, nj − y + 1)}
(φ2 − φ1)(nj + 1)
−π1jBeta(φ1; y + 1, nj − y + 1)
φ1(nj + 1)
]
+
b2j−1∑
y=0
{
π2jBeta(φ2; y + 1, nj − y + 1)
(1− φ2)(nj + 1)
−π0j{Beta(φ2; y + 1, nj − y + 1)− Beta(φ1; y + 1, nj − y + 1)}
(φ2 − φ1)(nj + 1)
}
,
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where b1j = floor(njλ1j), b2j = floor(njλ2j) and Beta(c; a, b) is the cumulative distribution
function of a beta distribution with the shape and scale parameters a and b, evaluated at
the value c. Although without closed forms, the following theorem can be shown to hold.
Theorem 3. The values of λ1j and λ2j that minimize the global decision error rate (6) are
the boundaries at which the posterior probabilities of H1 and H2, respectively, become more
likely than that of the H0.
The proof of this result appears in the Appendix. In practice, the values of λ1j and λ2j that
minimize the global decision error rate can be easily determined by a numerical search, as
b1j and b2j are integers between 0 and nj .
Compared to the local optimal design, the interval length (i.e., λ2j−λ1j) under the global
optimal design is wider (see Figure 2). This is because when we use the point-hypothesis
values of the local optimal approach (i.e., φ1 and φ2) as the endpoints of the composite
hypothesis for the global approach, the latter is more favorable to the null because the most
formidable competing hypotheses are then “diluted” by a continuum that is also far less
likely to contain ones. In addition, as shown in Figure 2, unlike the local optimal design, for
which λ1j and λ2j are invariant to nj , for the global optimal design, λ1j and λ2j depend on
nj even when the three hypotheses have equal prior probabilities. Despite these differences,
we note that the global optimal design is also long-memory coherent because λ1j < φ and
λ2j > φ.
Theorem 4. When setting π0j = π1j = π2j , the global optimal design is long-memory
coherent in the sense that the probability of dose escalation (or deescalation) is zero when
the observed toxicity rate pˆj at the current dose is higher (or lower) than the target toxicity
rate φ.
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In addition, as shown in the Appendix, the global optimal design has the convergence
property described in Theorem 5.
Theorem 5 Dose allocation in the global optimal interval design converges almost surely
to dose level j∗ if pj∗ ∈ (φ1, φ2) and dose level j∗ is the only dose satisfying pj∗ ∈ [φ1, φ2].
If no dose level satisfies pj ∈ (φ1, φ2) but φ ∈ [p1, pJ ], the global optimal interval design
would eventually oscillate almost surely between the two dose levels at which the associated
toxicity probabilities straddle the target interval. If there are multiple dose levels satisfying
pj ∈ (φ1, φ2), the global optimal interval design will converge almost surely to one of these
levels.
As for the practical implementation of this design, the same principle described in the
previous section can be used to specify the design parameters φ1, φ2 and πkj for the global
optimal design. The interval boundaries for the global optimal design do not have a closed
form, but can be easily determined using a numerical search. The interval boundaries of
the global optimal design depend on nj even when we set π0j = π1j = π2j , which makes
the implementation of the design slightly more complicated than that of the local optimal
design. That is, we need to find λ1j and λ2j for each possible value of nj before the initiation
of the trial. Once these boundaries are determined, the global optimal design can be easily
conducted by comparing the observed toxicity rate with the interval boundaries. Table 2
displays the interval boundaries of the global optimal design when the target toxicity rate
is 0.25 up to nj = 15. Thus for practical reasons, we may prefer to use the local optimal
design. The finite sample simulation described in the next section also suggests that the
local optimal design has better operating characteristics.
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3 Simulation studies
We used simulation studies to compare the operating characteristics of the proposed designs
with those of four available designs: the group up-and-down (GUD) design, the cumulative
cohort design (CCD), the modified toxicity probability interval (mTPI) design, and the
CRM. We assumed a total of J = 6 dose levels with a sample size of n = 36 patients in
12 cohorts of size 3. The target toxicity rate was φ = 0.25. In the proposed designs, we
set φ1 = 0.15, φ2 = 0.35 and assigned equal prior probabilities to three hypotheses with
π0j = π1j = π2j = 1/3. The same values of φ1 and φ2 were also used for the mTPI design.
For the CCD, following Ivanova et al. (2007), we set the tolerance interval as φ± 0.09. For
the GUD design, we escalated the dose when no toxicities were observed in the 3-patient
cohort, and deescalated the dose if any toxicities were observed in the 3-patient cohort,
as recommended by Gezmu and Flournoy (2006) (i.e., the (3, 0, 1) design according to
their terminology). The CRM was based on the model pj = a
exp(α)
j where the “skeleton”
aj = (0.01, 0.08, 0.25, 0.46, 0.65, 0.79) was chosen based on the model calibration method of
Lee and Cheung (2009). We assigned the unknown parameter α the least-informative prior
α ∼ N(0, 1.242) as proposed by Lee and Cheung (2011), under which each dose level has
an (approximately) equal prior probability of being the MTD. Skipping a dose level was not
allowed in the CRM. To make the designs more comparable, we applied the dose elimination
rule and isotonic dose selection rule, as described in Section 2.2.3, to all designs except
the CRM because that design has its own model-based safety and dose selection rules. We
simulated 10,000 trials. To avoid cherry-picking scenarios that are better suited to specific
methods, for each simulated trial, the toxicity scenario (i.e., the true toxicity probabilities
of the six doses) was randomly generated based on the approach of Paoletti, O’Quigley and
Maccario (2004), as follows:
1. Randomly select, with equal probabilities, one of the J dose levels as the MTD and
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denote this selected dose level by j.
2. Generate the toxicity probability of the MTD, pj = Φ(ǫj), where the random error
ǫj ∼ N(z(φ), σ20) with Φ(·) and z(·) denoting the cumulative density function (CDF)
and the inverse CDF of the standard normal distribution, respectively.
3. Generate pj−1 and pj+1 (i.e., the toxicity probabilities of two doses adjacent to the
MTD) under the constraint that pj is closest to φ. This can be done by generat-
ing pj−1 = Φ[z(pj) − I{z(pj)>z(φ)}{z(pj) − z(2φ − pj)} − ǫ2j−1] and pj+1 = Φ[z(pj) +
I{z(pj)<z(φ)}{z(2φ− pj)− z(pj)} + ǫ2j+1] where ǫj−1 ∼ N(µ1, σ21), ǫj+1 ∼ N(µ2, σ22), and
I(.) is an indicator function. For example, I{z(pj)>z(φ)} equals 1 if z(pj) > z(φ) and 0
otherwise.
4. Successively generate the toxicity probabilities for the remaining levels according to
pj−2 = Φ[z(pj−1) − ǫ2j−2] and pj+2 = Φ[z(pj+1) + ǫ2j+2], and pj−3 = Φ[z(pj−2) − ǫ2j−3]
and pj+3 = Φ[z(pj+2) + ǫ
2
j+3], and so on, where ǫj−2, ǫj−3 ∼ N(µ1, σ21) and ǫj+2, ǫj+3 ∼
N(µ2, σ
2
2).
In our simulation, we set σ0 = 0.05, σ1 = σ2 = 0.35, and controlled the average probability
difference around the target to be 0.07, 0.1 and 0.15 by varying the values of µ1 and µ2. For
illustration, Figure 3 shows 10 (out of 10,000) randomly generated dose-toxicity curves when
the average probability difference around the target was 0.1. We can see that these curves
demonstrate various shapes and locations of the MTD.
Table 3 shows the simulation results, including the selection percentage of the MTD, the
average percentage of patients treated at the MTD, the average toxicity rate, and the average
sample size. In addition, we reported two risk measures for the designs: (1) the risk of poor
allocation, defined as the percentage of simulation runs in which the number of patients
allocated to the MTD (say n
MTD
) is less than that of a standard non-sequential design
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(i.e., n
MTD
< n/J); and (2) the risk of high toxicity, which is defined as the percentage
of simulation runs in which the total number of toxicities is greater than nφ. These risk
measures are of great practical importance because they gauge the likelihood of a trial
turning out to be a “bad” trial (e.g., performing worse than a standard non-sequential trial)
under a specific design.
The simulation results show that all the designs, except the GUD design, generally have a
similar “average” level of performance regarding several factors, including the MTD selection
percentage, the average percentage of patients treated at the MTD, and the average toxicity
rate. Among the six designs under comparison, the CCD, mTPI, and global optimal designs
have particularly similar performance levels. One reason for such similarity is that the
decisions of dose transition in these designs are all based on the data observed at the current
dose. Given that the number of patients treated at a specific dose level is typically very small
(e.g., up to a few cohorts) and the toxicity outcome is discrete, the possible outcome patterns
are actually very limited. Consequently, although based on different statistical criteria,
these designs often end up with similar dose transition decisions and average performance
levels, especially after averaging across a large number of random scenarios. The GUD
design performs differently, yielding MTD selection percentages and average toxicity rates
comparable to those of the other designs, but allocating lower percentages of patients to
the MTD. For example, the percentages of patients allocated to the MTD under the GUD
design are about 5% and 10% lower than those of the other designs when the respective
average probability differences around the target are 0.1 and 0.15. This is because the GUD
design never remains at the same dose level, except when possibly allocating patients to the
lowest or highest dose. Therefore, it has a lower chance of staying at the MTD even when
the observed data indicate that the current dose is the MTD.
However, in terms of the risk of poor allocation decisions, the local optimal design and
GUD design stand out and substantially outperform the other competing designs. For ex-
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ample, under the local optimal design, the risk of poor allocation is 14.3% and 16.1% lower
than that under the CRM, and is 10.4% and 10.8% lower than that under the CCD when
the average probability difference around the target is 0.1 and 0.07. For the risk of high tox-
icity, the proposed local optimal design and GUD design also perform better than the other
designs. These results suggest that the use of the local optimal interval design decreases the
likelihood of conducting a poorly performing trial compared to the use of the other designs.
Such an improvement is of great practical importance because we rarely run a trial more
than a few times. What really concerns us is the likelihood of a clinical trial allocating too
few patients to the MTD or resulting in too many toxicities, not the trial design’s average
performance over thousands of runs, such as in a simulation study. Although the GUD
design has the lowest risk of poor allocation decisions, unfortunately on average it allocates
lower percentages of patients to the MTD than the other designs, as noted previously.
The CCD, global optimal design and local optimal design share similar interval-based dose
transition schemes, so differences in the design risks (of poor allocation and high toxicity)
should be due to the different choices of the interval width (i.e., λ1j and λ2j). The interval
width of the CCD (i.e., ±0.9) is wider than that of the local optimal design (i.e., about
0.5), and is chosen based on a numerical search to ensure the convergence of the design.
The wide (tolerance) interval of the CCD may restrict the freedom of dose movement and
consequently lead to a higher risk of staying at doses that are not close to the MTD. This
may also explain why the global optimal design has a higher risk of poor allocation decisions
and high toxicity than the local optimal design, as the former also has a wider interval than
the local optimal design (see Figure 2) due to the optimization over the whole support of pj .
The CRM is a model-based design that determines dose assignment based on the estimate of
a parametric dose-toxicity model. Oron et al. (2011) and Azriel (2012) reported that under
randomly-simulated dose-toxicity scenarios, the CRM often failed to provide coverage of the
MTD (up to 90% of the time), which can induce extra variations in the performance of the
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CRM (e.g., a higher risk of poor allocation decisions).
The above random-scenario-based simulation provides an objective comparison of dif-
ferent designs by averaging over a large number of plausible scenarios. However, it cannot
inform us of the performance of the designs under a specific toxicity scenario. Therefore,
we conducted another simulation study based on a set of prespecified dose-toxicity scenarios
with different locations of the MTD. The simulation results are shown in Table 4. Albeit
there is some variation, the general pattern is similar to that under the random selection of
simulated toxicity scenarios. That is, different designs yield roughly comparable “average”
performance levels (i.e., the MTD selection percentage and the average number of patients
allocated to the MTD), but the proposed local optimal design and the GUD design have
lower risks of poor allocation decisions or high toxicity than the other designs. Compared
to the local optimal design, the drawback of the GUD design is that on average it allocates
fewer patients to the MTD. One phenomenon that is more explicitly revealed by the fixed-
scenario simulation is that the relative performance of the CRM depends on how much the
assumed model structure (e.g., skeleton) deviates from the truth. The CRM performs better
than the other designs if the target dose is close to its prior estimate of the MTD (i.e., dose
level 3, for example, under scenarios 2 and 4), but performs worse than the other designs if
the target dose deviates from its prior estimate (e.g., under scenarios 1 and 5).
4 Conclusion
We have proposed a flexible framework for constructing interval designs by treating phase I
dose finding as a decision-making problem. We proposed local and global optimal interval
designs that minimize the decision error of dose assignment based on either point or compos-
ite hypotheses. We showed that the proposed designs have sound theoretical properties and
good numerical performance. The proposed local and global optimal designs are substan-
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tially easier to implement than the CRM, yet they yield performances that are comparable
to that of the CRM.
We have considered the local and global optimal designs, but the proposed decision-
making framework is very flexible. These designs can be easily modified to accommodate
different design objectives by specifying an appropriate object function to be minimized.
For example, noting that the local and global decision errors given in equations (2) and
(6) actually consist of different types of decision errors, we can propose minimax designs to
prevent the rate of any individual type of decision error from being too high.
In some cases, for safety reasons, we may be more concerned with incorrect dose escalation
than with incorrect dose deescalation. In these cases, we can classify the decision error, such
as equation (2), into errors of making incorrect decisions of escalation, deescalation and dose
level retainment. We then assign the appropriate weight to each type of error to reflect its
relative importance, and minimize the resulting objective function.
The proposed optimal interval designs use only the information observed from patients
treated at the current dose to make the decision of dose assignment, resulting in a particularly
easy-to-implement design structure. Somewhat surprisingly, our simulation studies show
that ignoring data information at other doses does not have a noticeable impact on the
performance of the design. The proposed designs on average perform as well as the CRM,
which utilizes all the data observed across the dose range based on a parametric dose-response
model. This phenomenon may have two explanations. On one hand, although the optimal
interval design uses only local information for dose assignment, it does use all the observed
data (across doses) to select the MTD at the end of the trial. On the other hand, using a dose-
response model to pool information across doses, such as in the CRM, is inevitably subject
to the influence of model misspecification. As a result, on average, borrowing information
across doses may not incur much performance gain.
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APPENDIX
A. Derivation of λ1j and λ2j for the local optimal interval design
We rewrite the decision error α(λ1j, λ2j) given in equation (2) as
α(λ1j, λ2j) = α1(λ1j) + α2(λ2j) + π0j + π1j ,
where
α1(λ1j) = π0jBin(njλ1j ;n, φ)− π1jBin(njλ1j;n, φ1)
α2(λ2j) = π2jBin(njλ2j − 1;n, φ2)− π0jBin(njλ2j − 1;n, φ).
Therefore, in order to minimize α(λ1j , λ2j), we can minimize α1(λ1j) and α2(λ2j) separately
with regard to λ1j and λ2j , respectively. To minimize α1(λ1j), let b1j = floor(njλ1j) and
note that
α1(λ1j) = π0jBin(njλ1j ;nj , φ)− π1jBin(njλ1j ;nj, φ1)
=
b1j∑
y=0
(
nj
y
)
{π0jφy(1− φ)nj−y − π1jφy1(1− φ1)nj−y}
=
b1j∑
y=0
π1j
(
nj
y
)
φy1(1− φ1)nj−y
{
π0j
π1j
(
φ
φ1
)y (
1− φ
1− φ1
)nj−y
− 1
}
.
Because φ > φ1,
(
φ
φ1
)y (
1−φ
1−φ1
)nj−y
monotonically increases with y. Therefore, given π1j
(
n
y
)
φy1(1−
φ1)
nj−y > 0, α1(λ1j) is minimized when
njλ1j = max
{
y :
π0j
π1j
(
φ
φ1
)y (
1− φ
1− φ1
)nj−y
≤ 1
}
. (7)
This leads to the solution
λ1j =
log
(
1− φ1
1− φ
)
+ n−1j log
(
π1j
π0j
)
log
(
φ(1− φ1)
φ1(1− φ)
) .
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It is worth noting that the condition
pi0j
pi1j
(
φ
φ1
)y (
1−φ
1−φ1
)nj−y ≤ 1 in equation (7) is equiva-
lent to
pr(H0j|y)
pr(H1j|y) ≤ 1
since
pr(H0j|y) = pr(H0j)f(y|H0j)
f(y)
=
π0j
(
n
y
)
φy(1− φ)nj−y
f(y)
pr(H1j|y) = pr(H1j)f(y|H0j)
f(y)
=
π0j
(
n
y
)
φy1(1− φ1)nj−y
f(y)
.
Therefore, λ1j is the boundary at which the posterior probability of H1j becomes more likely
than that of H0j .
In the same vein, it can be shown that
λ2j =
log( 1−φ
1−φ2
) + n−1j log(
pi0j
pi2j
)
log(φ2(1−φ)
φ(1−φ2)
)
,
and λ2j is the boundary at which the posterior probability of H2j becomes more likely than
that of H0j .
B. Proof of Theorem 1
When π0j = π1j = π2j , λ1j and λ2j are the likelihood-ratio hypothesis-testing boundaries, so
λ1j < φ < λ2j . Therefore,
pr(dose escalation|pˆj > φ) = pr(pˆj < λ1j |pˆj > φ) = 0
pr(dose deescalation|pˆj < φ) = pr(pˆj > λ2j |pˆj < φ) = 0.
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C. Proof of Theorem 3
αg(λ1j, λ2j)
= pr(H0j)
∫
f(pj|H0j)pr(R¯|pj,H0j) dpj + pr(H1j)
∫
f(pj|H1j)pr(E¯ |pj ,H1j) dpj
+pr(H2j)
∫
f(pj|H2j)pr(D¯|pj,H2j) dpj
= pr(H0j)
∫
f(pj|H0j)pr(mj ≤ njλ1j ormj ≥ njλ2j |pj,H0j) dpj
+pr(H1j)
∫
f(pj|H0j)pr(mj > njλ1j |pj,H1j) dpj
+pr(H2j)
∫
f(pj|H2)pr(mj < njλ2j |pj ,H2j) dpj
= pr(H0j)
b1j∑
y=0
∫
f(pj|H0j)f(y|pj,H0j) dpj + pr(H0j)− pr(H0j)
b2j−1∑
y=0
∫
f(pj|H0j)f(y|pj ,H0j) dpj
+pr(H1j)− pr(H1j)
b1j∑
y=0
∫
f(pj|H1j)f(y|pj,H1j) dpj + pr(H2j)
b2j−1∑
y=0
∫
f(pj|H2j)f(y|pj,H2j) dpj
= pr(H0j) + pr(H1j) +
b1j∑
y=0
{
pr(H0j)
∫
f(pj|H0j)f(y|pj,H0j) dpj − pr(H1j)
∫
f(pj|H1j)f(y|pj ,H1j) dpj
}
+
b2j−1∑
y=0
{
pr(H2j)
∫
f(pj|H2j)f(y|pj ,H2j) dpj − pr(H0j)
∫
f(pj|H0j)f(y|pj,H0j) dpj
}
= pr(H0j) + pr(H1j) +
b1j∑
y=0
f(y){pr(H0j |y)− pr(H1j|y)}+
b2j−1∑
y=0
f(y){pr(H2j |y)− pr(H0j|y)}
The last equality holds because
pr(Hkj|y) = pr(Hkj)
∫
f(pj|Hkj)f(y|pj, Hkj)dpj
f(y)
, k = 0, 1, 2.
Therefore, in order to minimize αg(λ1j , λ2j), we can minimize αg1(λ1j) =
∑b1j
y=0 f(y){pr(H0j |y)−
pr(H1j |y)} and αg2(λ2j) =
∑b2j−1
y=0 f(y){pr(H2j |y)− pr(H0j |y)} separately with regard to λ1j
and λ2j, respectively.
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Now,
pr(H0j |y) = pr(H0j)
∫
f(pj|H0j)f(y|pj, H0j)dpj
f(y)
=
π0j
∫ φ2
φ1
(φ2 − φ1)−1
(
n
y
)
pyj (1− pj)nj−y dpj
f(y)
=
π0j{Beta(φ2; j + 1, n− j + 1)−Beta(φ1; j + 1, n− j + 1)}
(φ2 − φ1)(nj + 1)f(y)
and similarly, it can be shown that
pr(H1j |y) = π1jBeta(φ1; j + 1, n− j + 1)
φ1(nj + 1)f(y)
.
Therefore,
αg1(λ1j) =
b1j∑
y=0
{pr(H0j|y)− pr(H1j |y)}
=
b1j∑
y=0
pr(H1j|y)
{
pr(H0j |y)
pr(H1j |y) − 1
}
=
b1j∑
y=0
pr(H1j|y)
{
π0jφ1
π1j(φ2 − φ1)
Beta(φ2; y + 1, nj − y + 1)
Beta(φ1; y + 1, nj − y + 1) −
1
π1j(φ2 − φ1) − 1
}
.
Because pr(H1j |y) ≥ 0, in order to establish that α1(λ1j) is minimized when
njλ1j = max
{
y :
pr(H0j |y)
pr(H1j |y) ≤ 1
}
, (8)
we need to show only that
Beta(φ2; y + 1, n− y + 1)
Beta(φ1; y + 1, n− y + 1) is a monotonic increasing function of
y. Letting y∗ = y + 1, and using the following property of the cumulative density function
(CDF) of the Beta distribution,
Beta(x, a, b) =
a+b−1∑
j=a
(a + b− 1)!
j!(a+ b− 1− j)!x
j(1− x)a+b−1−j
when a and b are integers, we have
Beta(φ2; y + 1, nj − y + 1) = Beta(φ2; y∗ + 1, nj − y∗ + 1) + (n+ 1)!
y!(n+ 1− y)!φ
y
2(1− φ2)nj+1−y
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where, as in our case, y and nj are integers. Let C(y) = (n+ 1)!/{y!(n + 1 − y)!}, then it
follows that
Beta(φ2; y + 1, nj − y + 1)
Beta(φ1; y + 1, nj − y + 1) =
Beta(φ2; y
∗ + 1, nj − y∗ + 1) + C(y)φy2(1− φ2)nj+1−y
Beta(φ1; y∗ + 1, nj − y∗ + 1) + C(y)φy1(1− φ1)nj+1−y
=
Beta(φ2; y
∗ + 1, nj − y∗ + 1)
Beta(φ1; y∗ + 1, nj − y∗ + 1)
1 +
C(y)φy2(1− φ2)nj+1−y
Beta(φ2; y
∗ + 1, nj − y∗ + 1)
1 +
C(y)φy1(1− φ1)nj+1−y
Beta(φ1; y
∗ + 1, nj − y∗ + 1)
=
Beta(φ2; y
∗ + 1, nj − y∗ + 1)
Beta(φ1; y∗ + 1, nj − y∗ + 1) ×
1 +
C(y)φy2(1− φ2)nj+1−y
nj+1∑
k=y∗+1
C(k)φk2(1− φ2)nj+1−k
1 +
C(y)φy1(1− φ1)nj+1−y
nj+1∑
k=y∗+1
C(k)φk1(1− φ1)nj+1−k
=
Beta(φ2; y
∗ + 1, nj − y∗ + 1)
Beta(φ1; y∗ + 1, nj − y∗ + 1) ×
1 + (
∑nj+1
k=y∗+1
C(k)
C(y)
( φ2
1−φ2
)k−y)−1
1 + (
∑nj+1
k=y∗+1
C(k)
C(y)
( φ1
1−φ1
)k−y)−1
.
Now because φ2 > φ1, it follows that
Beta(φ2; y + 1, nj − y + 1)
Beta(φ1; y + 1, nj − y + 1) <
Beta(φ2; y
∗ + 1, nj − y∗ + 1)
Beta(φ1; y∗ + 1, nj − y∗ + 1) .
Therefore,
Beta(φ2; y + 1, n− y + 1)
Beta(φ1; y + 1, n− y + 1) is a monotonic increasing function of y, and equation
(8) follows.
Along the same line, we can prove that αg2(λ2j) is minimized when
njλ2j = max
{
y :
pr(H2j |y)
pr(H0j |y) ≤ 1
}
.
D. Proof of Theorem 5
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It is known that Bayesian hypothesis testing is consistent in the sense that if Hkj is true,
pr(Hkj|nj) → 1 when nj → ∞ (Walker and Hjort, 2001). Now, according to Theorem 3,
the values of λ1j and λ2j that minimize the global decision error rate (6) are the boundaries
at which the posterior probabilities of H1 and H2, respectively, become more likely than
that of H0.Therefore, when nj → ∞, λ1j → φ1 and λ2j → φ2 as both λ1j and λ2j converge
to constants. The proof provided by Oron, Azriel and Hoff (2011) can be directly used to
obtain the result.
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Figure 1: Interval boundaries λ1j and λ2j changing with the values of φ1 and φ2 when the
target toxicity rate φ = 0.25 and π0j = π1j = π2j .
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Figure 2: Interval boundaries λ1j and λ2j for the local optimal design (triangles) and global
optimal design (circles) under different numbers of cumulative patients at the current dose
(nj) when φ = 0.25, φ1 = 0.15, φ2 = 0.35 and π0j = π1j = π2j . Under each design, the top
line is λ1j and the bottom line is λ2j.
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Figure 3: Ten randomly generated dose-toxicity curves based on the simulation procedure
described in Section 3. The dashed line indicates the target toxicity probability of 0.25.
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Table 1: Values of λ1j and λ2j under the local optimal interval design for different target
toxicity rates when φ1 = 0.6φ, φ2 = 1.4φ and π0j = π1j = π2j .
Interval Target toxicity rate φ
boundaries 0.15 0.2 0.25 0.3 0.35 0.4
λ1j 0.118 0.157 0.197 0.236 0.276 0.316
λ2j 0.179 0.238 0.298 0.358 0.419 0.479
Table 2: Interval boundaries and dose elimination boundaries for the global optimal designs
when the target toxicity rate φ = 0.25 with φ1 = 0.15 and φ2 = 0.35.
Number of cumulative patients treated at the current dose (nj)
Boundary 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
λ1j 0/1 0/2 0/3 0/4 0/5 0/6 0/7 1/8 1/9 1/10 1/11 1/12 1/13 1/14 2/15
λ2j 1/1 2/2 2/3 2/4 3/5 3/6 4/7 4/8 5/9 5/10 5/11 6/12 6/13 7/14 7/15
Elimination NA NA 3/3 3/4 3/5 4/6 4/7 4/8 5/9 5/10 6/11 6/12 6/13 7/14 7/15
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Table 3: Simulation results when the dose-toxicity scenarios are randomly generated.
Selection % % of patients Average Risk of Risk of Sample
Design of MTD at MTD toxicity rate poor allocation high toxicity size
Average probability difference around the target = 0.1
GUD 45.2 29.8 18.6 21.1 14.5 35.3
CCD 46.0 35.2 19.8 39.1 16.2 35.3
mTPI 44.8 35.3 19.8 39.9 16.9 35.2
CRM 44.7 35.4 19.3 43.0 16.9 35.2
Global optimal 45.4 35.5 19.9 41.7 17.6 35.2
Local optimal 46.2 33.0 19.2 28.7 14.8 35.3
Average probability difference around the target = 0.07
GUD 36.6 26.3 19.3 29.4 15.9 35.2
CCD 36.2 29.6 20.0 49.4 16.5 35.1
mTPI 36.1 29.8 20.0 50.7 17.3 35.1
CRM 33.3 28.6 19.5 54.7 17.5 35.1
Global optimal 36.6 29.6 20.1 51.5 18.0 35.1
Local optimal 37.0 28.5 19.5 38.6 15.5 35.1
Average probability difference around the target = 0.15
GUD 56.8 34.8 18.3 10.9 13.6 35.4
CCD 57.7 43.4 19.8 26.0 16.8 35.4
mTPI 57.6 44.0 20.1 26.9 18.1 35.4
CRM 59.8 44.7 19.6 26.6 17.9 35.4
Global optimal 57.5 44.1 20.1 27.7 18.1 35.4
Local optimal 57.6 43.4 19.0 18.0 15.5 35.3
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Table 4: Simulation results under six prespecified dose-toxicity scenarios. The target toxicity
rate of 0.25 is underlined.
Dose level Risk of Risk of
Design 1 2 3 4 5 6 poor allocation high toxicity
Scenario 1 Pr(toxicity) 0.25 0.35 0.5 0.6 0.7 0.8
GUD Selection (%) 57.3 25.0 3.4 0.3 0.0 0.0 5.2 60.7
# patients 21.0 9.2 2.4 0.3 0.0 0.0
CCD Selection (%) 60.8 23.0 1.5 0.0 0.0 0.0 19.8 52.8
# patients 22.4 8.8 1.4 0.1 0.0 0.0
mTPI Selection (%) 58.2 25.3 1.8 0.1 0.0 0.0 23.6 53.7
# patients 21.8 9.3 1.5 0.1 0.0 0.0
CRM Selection (%) 55.6 26.2 1.1 0.0 0.0 0.0 22.9 52.9
# patients 21.9 9.3 1.4 0.1 0.0 0.0
Global optimal Selection (%) 59.4 24.5 1.6 0.0 0.0 0.0 24.8 54.1
# patients 21.5 9.5 1.5 0.1 0.0 0.0
Local optimal Selection (%) 63.0 20.6 1.6 0.1 0.0 0.0 13.8 53.4
# patients 22.9 8.0 1.7 0.2 0.0 0.0
Scenario 2 Pr(toxicity) 0.03 0.06 0.1 0.25 0.35 0.5
GUD Selection (%) 0.0 1.1 21.6 52.4 21.0 3.9 27.4 0.5
# patients 4.4 6.7 10.1 9.6 4.1 1.1
CCD Selection (%) 0.0 1.1 19.1 54.3 22.6 2.8 35.4 5.0
# patients 3.7 4.9 8.8 12.4 5.2 1.0
mTPI Selection (%) 0.0 1.1 18.1 53.4 24.1 3.3 37.3 6.4
# patients 3.7 4.8 8.5 12.5 5.4 1.1
CRM Selection (%) 0.0 2.8 26.1 56.4 14.1 0.6 40.4 4.4
# patients 3.7 5.2 10.7 12.0 3.8 0.5
Global optimal Selection (%) 0.0 1.3 18.8 52.3 24.5 3.1 38.6 7.2
# patients 3.7 4.8 8.3 12.5 5.6 1.1
Local optimal Selection (%) 0.0 1.0 21.3 55.1 20.5 2.1 17.7 3.2
# patients 4.0 5.3 9.3 11.5 4.7 1.2
Scenario 3 Pr(toxicity) 0.01 0.04 0.06 0.1 0.25 0.35
GUD Selection (%) 0.0 0.0 2.0 22.0 54.0 22.0 35.0 0.0
# patients 3.6 4.7 6.1 9.6 8.2 3.9
CCD Selection (%) 0.0 0.0 2.0 19.0 58.0 21.0 40.0 1.0
# patients 3.1 4.0 5.2 8.0 11.0 4.8
mTPI Selection (%) 0.0 0.0 2.0 19.0 57.0 22.0 41.0 2.0
# patients 3.1 4.0 5.1 7.7 11.0 5.0
CRM Selection (%) 0.0 0.0 5.0 34.0 52.0 9.0 51.0 0.0
# patients 3.1 3.7 7.2 9.4 9.7 2.9
Global optimal Selection (%) 0.0 0.0 3.0 18.0 56.0 23.0 41.0 2.0
# patients 3.1 4.0 5.2 7.6 11.1 5.0
Local optimal Selection (%) 0.0 0.0 3.0 21.0 65.0 11.0 31.0 1.0
# patients 3.5 4.3 5.2 9.0 10.2 3.7
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Table 4 continued.
Dose level Risk of Risk of
Design 1 2 3 4 5 6 poor allocation high toxicity
Scenario 4 Pr(toxicity) 0.05 0.1 0.25 0.32 0.5 0.6
GUD Selection (%) 0.4 18.9 49.2 26.9 4.2 0.4 19.1 2.4
# patients 6.8 11.9 10.4 5.3 1.4 0.2
CCD Selection (%) 0.5 18.8 50.4 27.4 2.8 0.2 34.0 13.2
# patients 4.5 9.5 14.0 6.5 1.4 0.1
mTPI Selection (%) 0.5 18.0 49.1 29.0 3.1 0.2 36.3 15.6
# patients 4.5 9.1 14.1 6.7 1.4 0.1
CRM Selection (%) 0.1 18.1 61.1 19.5 1.1 0.0 31.3 14.2
# patients 4.4 9.7 15.7 5.2 0.8 0.1
Global optimal Selection (%) 0.7 18.3 49.0 28.8 3.0 0.2 37.7 16.8
# patients 4.5 9.0 14.1 6.9 1.5 0.1
Local optimal Selection (%) 0.4 19.0 53.0 24.7 2.8 0.1 27.8 9.8
# patients 5.1 10.2 13.2 5.9 1.6 0.2
Scenario 5 Pr(toxicity) 0.01 0.02 0.03 0.04 0.05 0.25
GUD Selection (%) 0.0 0.0 0.1 0.5 17.0 82.5 19.4 0.0
# patients 3.3 3.5 3.8 4.7 9.6 11.0
CCD Selection (%) 0.0 0.0 0.1 0.5 15.2 84.2 11.6 0.0
# patients 3.2 3.4 3.7 3.9 6.2 15.6
mTPI Selection (%) 0.0 0.0 0.1 0.5 14.3 85.0 11.6 0.0
# patients 3.2 3.4 3.7 3.9 6.0 15.8
CRM Selection (%) 0.0 0.1 2.1 9.8 18.1 69.9 33.9 0.0
# patients 3.2 3.5 4.7 5.1 7.0 12.5
Global optimal Selection (%) 0.0 0.0 0.2 0.5 14.5 84.8 11.6 0.0
# patients 3.2 3.4 3.7 3.9 5.8 16.0
Local optimal Selection (%) 0.0 0.0 0.1 0.7 16.8 82.4 14.1 0.0
# patients 3.3 3.5 3.8 4.0 7.6 13.8
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